This study aims to evaluate the effect of variantsin pharmacogenes SLC29A1, DCK, ABCB1, GSTM1and GSTT1, as well as laboratory and AML-relatedparameters on clinical outcome in adult AMLpatients. The gene discussed is SLC29A1; the disease is acute myeloid leukemia.